ProQR Therapeutics Q1 2024 GAAP EPS €(0.09) Misses €(0.07) Estimate, Sales €4.450M Beat €3.144M Estimate
Portfolio Pulse from Benzinga Newsdesk
ProQR Therapeutics reported its Q1 2024 earnings with a GAAP EPS of €(0.09), missing the estimate of €(0.07). However, their sales of €4.450M exceeded the estimate of €3.144M.
May 09, 2024 | 11:56 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ProQR Therapeutics Q1 2024 earnings report showed a miss on GAAP EPS estimates but exceeded sales forecasts.
The miss on the GAAP EPS estimate may concern some investors, potentially putting downward pressure on the stock. However, the beat on sales estimates could offset this negative impact by indicating stronger than expected revenue generation. The mixed results make the short-term impact on the stock price uncertain, hence a neutral score.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100